home

stacks_image_DE3BF625-DF09-4DC7-A1C0-1678357A2AF0

JS Genetics Inc, develops and markets proprietary, low cost, high value DNA diagnostic tests for underserved medical conditions in newborns, children, and adolescents. This focus grew out of the recognition that most genetic tests require blood samples, have longer turn-around times, and are expensive. The Company's principle strategy is to internally develop tests using cheek swabs for sample collection and a PCR based testing platform to bring to market accurate, convenient and cost effective DNA screening tests for adolescents focused in three key areas of developmental disorders:

Physical Developmental Disorders: Turner Syndrome, Klinefelter Syndrome, & Down's Syndrome
Cognitive Developmental Disorders: Dyslexia
Behavioral Developmental Disorders: Fragile X

In addition, we have a novel therapeutic compound under development for the treatment of Periventricular White Matter Injury (PWMI) in premature infants. This program is currently in preclinical testing.

The underlying technology for our Turner syndrome and Dyslexia tests was developed at Yale University and is exclusively licensed to JS Genetics. JS Genetics' scientific approach and the clinical utility of its products have been validated by the receipt since 2006 of seven NIH Small Business Innovation Research (SBIR) awards totaling $3.4 million of which $1.8 million has been allocated for use in 2010-2011. These NIH grants have funded our R&D initiatives.

JS Genetics’ first product, a Turner Syndrome Screening Test, is scheduled to be commercially available in the second quarter of 2010. Our approach, which involves PCR-based pyrosequencing technology using patient samples from a cheek swab, reduces our internal cost, and allows us to offer our product at a 50%-60% discount in price from the Karyotype (~$2200), the current definitive test for Turner syndrome. We believe that this lower price point, along with the convenience of using a cheek swab instead of drawing blood, will make our diagnostic test the best screening option for Turner syndrome.

Our second product, based on the same underlying technology as our Turner’s test, is a screening test for Klinefelter syndrome; the most common genetic abnormality in males. This product is currently in clinical validation trials and is scheduled to be commercialized in the first quarter of 2011.

We aim to commercialize follow-on tests for identification of Fragile X and Trisomy 21 as well as offer a test for predisposition to Dyslexia in the next 18-36 months.